Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 19, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Upstart Holdings, Inc.and Certain Officers – UPST

View original at globenewswire.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Upstart Holdings, Inc.and Certain Officers – UPST NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Upstart Holdings, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Upstart expected to generate Q4 2025 revenue of approximately $288 million

    60% confidence
  • Defendants made materially false and misleading statements regarding Upstart's business, operations, and prospects: (i) Model 22 frequently overreacted to negative macroeconomic signals in its risk-separation processes; (ii) Model 22's overall accuracy and propensity to increase loan approval rates was overstated; (iii) Model 22's overly conservative assessment was having a significant negative impact on revenues, rendering FY 2025 guidance unreliable and/or unrealistic; (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times

    60% confidence
  • Upstart had knowingly calibrated its AI model to be more conservative on the credit side in earlier parts of Q3 2025, and that Model 22's overresponsiveness to macroeconomic signals would continue to negatively impact Q4 2025 revenues

    60% confidence
  • Upstart raised FY 2025 revenue guidance to approximately $1.01 billion, maintaining fee revenue guidance at approximately $920 million

    60% confidence
  • Upstart substantially raised FY 2025 revenue guidance to approximately $1.055 billion with fee revenue of approximately $990 million, attributing the increase to improvements in performance driven by Model 22

    60% confidence
  • Upstart issued FY 2025 financial guidance of approximately $1 billion total revenue and approximately $920 million in fee revenue

    60% confidence
  • Model 22 had overreacted to macroeconomic signals during Q3 2025, reducing borrower approvals and conversion rates and negatively impacting revenues

    60% confidence
  • Upstart's AI models more accurately quantify the true risk of a loan through risk separation, leading to higher approvals and lower interest rates relative to traditional lending practices and providing more predictable returns to capital partners including banks, credit unions, and institutional investors

    60% confidence
  • Upstart negatively revised its FY 2025 revenue guidance to approximately $1.035 billion and reduced fee revenue outlook to approximately $946 million from $990 million

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com